The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of September 2024. This month there are two technology appraisals that impact upon primary care.
The Vibegron for treating symptoms of overactive bladder syndrome technology appraisal has been published. This treatment is an option for treating the symptoms of overactive bladder syndrome in adults. It is only recommended if antimuscarinic medicines are not suitable, do not work well enough or have unacceptable side effects. It is recommended that the range of suitable treatments are discussed with consideration given to the advantages and disadvantages of all the options, then the least expensive suitable treatment should be used.
The Empagliflozin for treating type 2 diabetes in people 10 to 17 years technology appraisal has been terminated. The manufacturer did not provide an evidence submission and therefore NICE is unable to make a recommendation for empagliflozin for this indication.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.